Harvard Bioscience vs Standard Biotools
Harvard Bioscience and Standard Biotools are similar in size: $86.5m and $85.3m of revenue in their latest fiscal years. Standard Biotools grew faster (-6.2% against -8.1%). Harvard Bioscience kept more of each dollar of sales as profit: a net margin of -65.5% against -87.8%. Standard Biotools carries less debt relative to equity (0.1% against 291.2%).
| Latest fiscal year | Harvard BioscienceHBIO, 2025 | Standard BiotoolsLAB, 2025 |
|---|---|---|
| Revenue | $86.5m | $85.3m |
| Revenue growth | -8.1% | -6.2% |
| Net income | −$56.7m | −$74.9m |
| Operating margin | -56.1% | -129.2% |
| Net margin | -65.5% | -87.8% |
| Return on equity | -147.1% | -16.7% |
| Free cash flow | $5.5m | −$82.6m |
| Cash | $8.6m | $121m |
| Total debt | $40.0m | $299,000 |
| Debt to equity | 291.2% | 0.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | 339 | 389 |
| Market value | $40.1m | $241m |
| Price vs our value range | — | — |
| Moat score | 56 (Moderate) | 20 (Weak) |
| Insider trades, 12 months | 5 buys, 0 sales | 15 buys, 0 sales |